A retrospective, observational, multicenter study of safety and efficacy of daratumumab for refractory autoimmune cytopenias
Latest Information Update: 06 Aug 2021
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone
- Indications Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 06 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association